
浏览全部资源
扫码关注微信
1.中国中医科学院 中药研究所,北京 100700
2.中国中医科学院 青蒿素研究中心,北京 100700
崔钊,在读硕士,从事青蒿素类化合物抗肿瘤机制研究,Tel:010-64041008,E-mail:cuizhao1124@126.com
李沧海,博士,副研究员,硕士生导师,从事青蒿素类化合物抗疟机制研究,Tel:010-64041008,E-mail:chli@icmm.ac.cn
收稿日期:2021-02-22,
网络出版日期:2021-04-14,
纸质出版日期:2021-06-20
移动端阅览
崔钊,李硕,王华晶等.双氢青蒿素对HepG2细胞氧化损伤和能量代谢的影响及其与索拉非尼的协同作用[J].中国实验方剂学杂志,2021,27(12):24-32.
CUI Zhao,LI Shuo,WANG Hua-jing,et al.Effect of Dihydroartemisinin on Oxidative Damage and Energy Metabolism of HepG2 Cells and Its Synergistic Effect with Sorafenib[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(12):24-32.
崔钊,李硕,王华晶等.双氢青蒿素对HepG2细胞氧化损伤和能量代谢的影响及其与索拉非尼的协同作用[J].中国实验方剂学杂志,2021,27(12):24-32. DOI: 10.13422/j.cnki.syfjx.20211202.
CUI Zhao,LI Shuo,WANG Hua-jing,et al.Effect of Dihydroartemisinin on Oxidative Damage and Energy Metabolism of HepG2 Cells and Its Synergistic Effect with Sorafenib[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(12):24-32. DOI: 10.13422/j.cnki.syfjx.20211202.
目的
2
探讨双氢青蒿素(DHA)对HepG2细胞的增殖抑制作用,通过细胞氧化损伤及能量代谢交互通路的影响阐明其作用机制;并通过与索拉非尼(Sora)联用,探讨其联合用药的可能性。
方法
2
选用HepG2细胞和SW480细胞,细胞增殖与活性检测(CCK-8)法分别得到DHA与Sora的半数抑制浓度(IC
50
);Chou-Talalay法分析DHA与Sora联用的联用指数(CI)。选用HepG2细胞,分为正常组,DHA单用组(10 µmol·L
-1
),Sora单用组(5 µmol·L
-1
)和DHA与Sora联用组(DHA 10 µmol·L
-1
,Sora 5 µmol·L
-1
),药物孵育8~12 h后,糖酵解速率试剂盒检测细胞糖酵解功能,线粒体压力试剂盒检测线粒体氧化磷酸化功能;DCFH-DA活性氧(ROS)探针检测细胞内ROS水平变化;脂质过氧化物丙二醛(MDA)检测试剂盒检测细胞内MDA水平变化;蛋白免疫印迹法(Western blot)检测细胞内血红素氧合酶1(HO-1)和谷氨酸半胱氨酸连接酶催化亚基(GCLC)蛋白的水平变化。
结果
2
与正常组比较,DHA单用组能够显著抑制HepG2细胞的线粒体氧化磷酸化ATP合成能力和糖酵解速率(
P
<
0.01),升高细胞内ROS和MDA水平(
P
<
0.05),降低HO-1,GCLC水平(
P
<
0.05);DHA与Sora联用在HepG2和SW480细胞中均具有较好的协同抑制细胞增殖作用,其CI值
<
0.9;与DHA单用组比较,DHA与Sora联用组对HepG2细胞的线粒体氧化磷酸化ATP合成和糖酵解的抑制程度均显著增强(
P
<
0.01);细胞内的ROS和MDA水平均显著升高(
P
<
0.01);细胞内抗氧化相关蛋白HO-1,GCLC水平均显著降低(
P
<
0.01)。
结论
2
DHA可能通过降低HepG2细胞内的HO-1,GCLC水平,升高ROS使MDA水平增加,并造成细胞线粒体氧化损伤,抑制细胞糖酵解能力以及氧化磷酸化能力,从而抑制HepG2细胞增殖;DHA与Sora联用具有协同抑制HepG2细胞增殖的作用,其机制可能与协同造成细胞氧化损伤从而影响线粒体电子传递链,抑制细胞能量代谢有关。
Objective
2
To explore the inhibitory effect of dihydroartemisinin (DHA) on the proliferation of HepG2 cells, elucidate the mechanism from the perspectives of oxidative damage and energy metabolism, and discuss the possibility of combined use of DHA with sorafenib (Sora).
Method
2
Cell counting kit-8 (CCK-8) assay was used to obtain the 50% inhibitory concentration (IC
50
) of DHA and Sora on HepG2 and SW480 cells and Chou-Talalay method was used to obtain the combination index (CI) of DHA and Sora. HepG2 cells were classified into the control group, DHA group (10 µmol·L
-1
), Sora group (5 µmol·L
-1
), and DHA + Sora group (DHA 10 µmol·L
-1
, Sora 5 µmol·L
-1
) and then incubated with corresponding drugs for 8-12 h. Seahorse XF glycolytic rate assay kit and cell mito stress test kit were employed to respectively detect the glycolysis function of cells and oxidative phosphorylation function of mitochondria. DCFH-DA and lipid peroxidation MDA assay kit were separately used to analyze the intracellular levels of reactive oxygen species (ROS) and malondialdehyde (MDA). Western blot was applied to determine the intracellular levels of heme oxygenase-1 (HO-1) and glutamate-cysteine ligase catalytic subunit (GCLC).
Result
2
Compared with the control group, DHA alone inhibited the ATP synthesis in mitochondrial oxidative phosphorylation and glycolysis (
P
<
0.01), increased the levels of intracellular ROS and MDA (
P<
0.05), and decreased the levels of HO-1 and GCLC (
P<
0.05) in HepG2 cells. DHA and Sora had synergistic inhibitory effect on proliferation of HepG2 and SW480 cells, with CI
<
0.90. The DHA + Sora group showed stronger suppression of ATP synthesis in mitochondrial oxidative phosphorylation and glycolysis (
P
<
0.01), higher levels of intracellular ROS and MDA (
P<
0.01), and lower levels of intracellular antioxidation-related proteins HO-1 and GCLC in HepG2 cells (
P<
0.01) than the DHA group.
Conclusion
2
DHA may increase the level of MDA by reducing HO-1 and GCLC and increasing ROS in HepG2 cells, which results in mitochondria oxidative damage, restricts cell glycolysis and mitochondrial oxidative phosphorylation, and thus finally inhibits the proliferation of HepG2 cells. DHA and Sora have synergistic inhibitory effect on the proliferation of HepG2 and SW480 cells, and the mechanism may be related to the synergistic oxidative damage that affects the mitochondrial electron transport chain and suppresses cell energy metabolism.
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 68 ( 6 ): 394 - 424 .
PALMER D H . Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med , 2008 , 359 ( 23 ): 2498 - 2499 .
SIEGEL A B , OLSEN S K , MAGUN A , et al . Sorafenib:where do we go from here? [J]. Hepatology , 2010 , 52 ( 1 ): 360 - 369 .
ABDEL-RAHMAN O , LAMARCA A . Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib:a systematic-review and Meta-analysis of the impact on survival [J]. Expert Rev Gastroenterol Hepatol , 2017 , 11 ( 1 ): 75 - 83 .
LU X , EFFERTH T . Repurposing of artemisinin-type drugs for the treatment of acute leukemia [J]. Semin Cancer Biol , 2020 , doi: 10.1016/j.semcancer.2020.05.016 http://dx.doi.org/10.1016/j.semcancer.2020.05.016 .
EFFERTH T . From ancient herb to modern drug:artemisia annua and artemisinin for cancer therapy [J]. Semin Cancer Biol , 2017 , 46 : 65 - 83 .
ELING N , REUTER L , HAZIN J , et al . Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells [J]. Oncoscience , 2015 , 2 ( 5 ): 517 - 532 .
LIN R , ZHANG Z , CHEN L , et al . Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells [J]. Cancer Lett , 2016 , 381 ( 1 ): 165 - 175 .
XU W , WANG H , TANG T , et al . Effect of dihydroartemisinin on plasmodium NADH-dependent glutamate synthase:the implication in malaria management [J]. Am J Chin Med , 2019 , 47 ( 6 ): 1325 - 1343 .
EFFERTH T . Cancer combination therapies with artemisinin-type drugs [J]. Biochem Pharmacol , 2017 , 139 : 56 - 70 .
LI Z J , DAI H Q , HUANG X W , et al . Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma [J]. Acta Pharmacol Sin , 2021 , 42 ( 2 ): 301 - 310 .
赵丽凤 , 李晓强 , 任汝静 , 等 . 三氧化二砷联合双氢青蒿素对THP-1细胞增殖及凋亡的影响 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 17 ): 42 - 48 .
WARBURG O . On respiratory impairment in cancer cells [J]. Science , 1956 , 124 ( 3215 ): 269 - 270 .
WARBURG O . On the origin of cancer cells [J]. Science , 1956 , 123 ( 3191 ): 309 - 314 .
马冀 , 崔钊 , 王华晶 , 等 . 不同抗疟药物对红内期恶性疟原虫3D7线粒体呼吸的影响 [J]. 中国临床药理学与治疗学 , 2020 , 25 ( 11 ): 1201 - 1213 .
COBBOLD S A , VAUGHAN A M , LEWIS I A , et al . Kinetic flux profiling elucidates two independent acetyl-CoA biosynthetic pathways in Plasmodium falciparum [J]. J Biol Chem , 2013 , 288 ( 51 ): 36338 - 36350 .
KE H , LEWIS I A , MORRISEY J M , et al . Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle [J]. Cell Rep , 2015 , 11 ( 1 ): 164 - 174 .
LI S , HUANG P , GAN J , et al . Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 [J]. Eur J Pharmacol , 2019 , 854 : 232 - 239 .
GAO P , SHEN S , LI X , et al . Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis [J]. Drug Des Devel Ther , 2020 , 14 : 2091 - 2100 .
CHOU T C . Theoretical basis,experimental design,and computerized simulation of synergism and antagonism in drug combination studies [J]. Pharmacol Rev , 2006 , 58 ( 3 ): 621 - 681 .
GALLAMINI A , ZWARTHOED C , BORRA A . Positron emission tomography (PET) in oncology [J]. Cancers (Basel) , 2014 , 6 ( 4 ): 1821 - 1889 .
BRAS M , QUEENAN B , SUSIN S A . Programmed cell death via mitochondria:different modes of dying [J]. Biochemistry (Mosc) , 2005 , 70 ( 2 ): 231 - 239 .
PIANTADOSI C A , ZHANG J . Mitochondrial generation of reactive oxygen species after brain ischemia in the rat [J]. Stroke , 1996 , 27 ( 2 ): 327 - 331 .
AVERY S V . Molecular targets of oxidative stress [J]. Biochem J , 2011 , 434 ( 2 ): 201 - 210 .
BLAJSZCZAK C , BONINI M G . Mitochondria targeting by environmental stressors:implications for redox cellular signaling [J]. Toxicology , 2017 , 391 : 84 - 89 .
LOBODA A , DAMULEWICZ M , PYZA E , et al . Role of Nrf2/HO-1 system in development,oxidative stress response and diseases:an evolutionarily conserved mechanism [J]. Cell Mol Life Sci , 2016 , 73 ( 17 ): 3221 - 3247 .
PIANTADOSI C A , CARRAWAY M S , BABIKER A , et al . Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1 [J]. Circ Res , 2008 , 103 ( 11 ): 1232 - 1240 .
LU S C . Regulation of glutathione synthesis [J]. Mol Aspects Med , 2009 , 30 ( 1/2 ): 42 - 59 .
王士群 , 朱宇珍 , 郑学宝 . Chou-Talalay在抗肿瘤联合用药中的研究应用概况 [J]. 中国现代应用药学 , 2013 , 30 ( 4 ): 449 - 453 .
0
浏览量
19
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621